5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 32026-10-08NCT07165028
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)HER2-positive Advanced Gastric Cancer; HER2-positive Gastroesophageal Junction AdenocarcinomaActive, not recruitingNot stated2026-08-20NCT05993234
DESTINY Breast Respond HER2-(Ultra)Low EuropeNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderRecruitingNot stated2026-08-19NCT05945732
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorderRecruitingPhase 32026-07-22NCT05253651
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasmRecruitingPhase 2 / Phase 32024-11-06NCT05254171